All In Biotech

Free tool

FAERS Monitor: Cometriq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203756 or its brand name (Cometriq, Cabozantinib S-Malate). Reports on generic versions are filed under their own applications.

Reports

5,563

Serious

3,912

70% of reports

Hospitalization

2,447

Death reported

976

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,109
  • diarrhoea1,034
  • fatigue713
  • nausea516
  • malignant neoplasm progression477
  • decreased appetite452
  • asthenia333
  • stomatitis332
  • weight decreased329
  • death317
  • vomiting301
  • palmar-plantar erythrodysaesthesia syndrome268
  • hypertension259
  • pain in extremity227
  • rash205

Reports by year received

View as table
YearReports
20111
20122
2013214
2014304
2015304
2016147
2017518
2018626
2019505
2020419
2021605
2022637
2023502
2024288
2025285
2026206

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,596 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (500). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
diarrhoeaSignal1,0346.15.74,499
off label useSignal1,1094.84.53,465
fatigueSignal7133.53.21,294
astheniaSignal3333.43.0556
nauseaSignal5162.52.3465
vomitingSignal3012.42.2255
rash2051.81.671
death3171.41.336
malignant neoplasm progression4770.00.01,801,072
decreased appetite4520.00.01,706,476
stomatitis3320.00.01,252,419
weight decreased3290.00.01,241,067
palmar-plantar erythrodysaesthesia syndrome2680.00.01,010,257
hypertension2590.00.0976,203
pain in extremity2270.00.0855,123

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.